These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14610621)

  • 21. Recruitment of Oligoclonal Viral-Specific T cells to Kill Human Tumor Cells Using Single-Chain Antibody-Peptide-HLA Fusion Molecules.
    Noy R; Haus-Cohen M; Oved K; Voloshin T; Reiter Y
    Mol Cancer Ther; 2015 Jun; 14(6):1327-35. PubMed ID: 25852061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide.
    Vessey SJ; Barouch DH; McAdam SN; Tussey LG; Davenport MA; O'Callaghan CA; Bell JI; McMichael AJ; Jakobsen BK
    Eur J Immunol; 1997 Apr; 27(4):879-85. PubMed ID: 9130639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies.
    Denkberg G; Klechevsky E; Reiter Y
    J Immunol; 2002 Oct; 169(8):4399-407. PubMed ID: 12370373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
    Lustgarten J
    Cancer Immunol Immunother; 2003 Dec; 52(12):751-60. PubMed ID: 12827309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
    Hernández J; Lee PP; Davis MM; Sherman LA
    J Immunol; 2000 Jan; 164(2):596-602. PubMed ID: 10623800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
    Oved K; Lev A; Noy R; Segal D; Reiter Y
    Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo.
    Echchannaoui H; Petschenka J; Ferreira EA; Hauptrock B; Lotz-Jenne C; Voss RH; Theobald M
    Mol Ther; 2019 Jan; 27(1):261-271. PubMed ID: 30528087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.
    Dahan R; Gebe JA; Preisinger A; James EA; Tendler M; Nepom GT; Reiter Y
    J Autoimmun; 2013 Dec; 47():83-93. PubMed ID: 24090977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anergy induction by dimeric TCR ligands.
    Appel H; Seth NP; Gauthier L; Wucherpfennig KW
    J Immunol; 2001 Apr; 166(8):5279-85. PubMed ID: 11290814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of NY-ESO-1
    Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
    Front Immunol; 2021; 12():644520. PubMed ID: 33833762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.
    Lev A; Noy R; Oved K; Novak H; Segal D; Walden P; Zehn D; Reiter Y
    Proc Natl Acad Sci U S A; 2004 Jun; 101(24):9051-6. PubMed ID: 15184663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
    Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
    Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
    Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
    J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody.
    Bhattacharya R; Xu Y; Rahman MA; Couraud PO; Romero IA; Weksler BB; Weidanz JA; Bickel U
    J Cell Physiol; 2010 Nov; 225(3):664-72. PubMed ID: 20506235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex.
    Hoffmann TK; Donnenberg VS; Friebe-Hoffmann U; Meyer EM; Rinaldo CR; DeLeo AB; Whiteside TL; Donnenberg AD
    Cytometry; 2000 Dec; 41(4):321-8. PubMed ID: 11084618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
    Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
    PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
    Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
    J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
    Carstens C; Newman DK; Bohlen H; König A; Koch N
    Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.